Literature DB >> 26663262

Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.

Taku Fujimura1, Sadanori Furudate1, Aya Kakizaki1, Yumi Kambayashi1, Takahiro Haga1, Akira Hashimoto1, Setsuya Aiba1.   

Abstract

Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato-oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.
© 2015 Japanese Dermatological Association.

Entities:  

Keywords:  PD-1/PD-L1 blockade; contact immunotherapy; immunohistochemical staining; melanoma; nivolumab

Mesh：

Substances：

Year:  2015        PMID： 26663262     DOI： 10.1111/1346-8138.13229

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


  12 in total

Review 1.  Melanoma and Immune Checkpoint Inhibitors.

Authors:  Masutaka Furue; Takamichi Ito; Naoko Wada; Maiko Wada; Takafumi Kadono; Hiroshi Uchi
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

Review 2.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade.

Authors:  Elizabeth H Byrne; David E Fisher
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

Review 3.  Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata.

Authors:  Kun-Wei Lai; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2022-09-22

4.  Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.

Authors:  Nicholas Gulati; Richard D Carvajal; Michael A Postow; Jedd D Wolchok; James G Krueger
Journal:  Exp Dermatol       Date:  2016-07       Impact factor: 3.960

Review 5.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

6.  Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.

Authors:  Sadanori Furudate; Taku Fujimura; Yumi Kambayashi; Takanori Hidaka; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2016-10-17

7.  Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis.

Authors:  Shelley J E Hwang; Benjamin Y Kong; Shaun Chou; Deepal Wakade; Matteo S Carlino; Pablo Fernandez-Penas
Journal:  Case Rep Med       Date:  2017-01-15

8.  Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.

Authors:  Taku Fujimura; Takanori Hidaka; Yumi Kambayashi; Sadanori Furudate; Aya Kakizaki; Hisayuki Tono; Akira Tsukada; Takahiro Haga; Akira Hashimoto; Ryo Morimoto; Takuhiro Yamaguchi; Tadao Takano; Setsuya Aiba
Journal:  Oncotarget       Date:  2017-04-13

9.  Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

Authors:  Kayo Tanita; Taku Fujimura; Yumi Kambayashi; Akira Tsukada; Yota Sato; Akira Hashimoto; Setsuya Aiba
Journal:  Case Rep Oncol       Date:  2018-02-15

10.  Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.

Authors:  Ivana Lameiras Gibbons; Marina Sonagli; Eduardo Bertolli; Mariana Petaccia de Macedo; Clovis Antonio Lopes Pinto; João Pedreira Duprat Neto
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.